Abbott’s UltiSynq lead receives simultaneous FDA and EU approvals
Abbott announced that its UltiSynq defibrillation lead, which combines conduction system pacing with defibrillation, has been approved by the U.S. FDA and received a CE mark in Europe. The approvals were based on the ASCEND CSP IDE trial, which showed a 97.5% major complication‑free rate and a 98.5% successful implantation rate at three months in 205 patients. Abbott said the lead expands its cardiac rhythm management portfolio.
Why it matters
The dual approvals give Abbott a new product option in both the U.S. and European markets, potentially increasing sales in the large ICD and CRT‑D segments (about 150,000 U.S. and 140,000 European implants annually). The FDA’s breakthrough device designation may accelerate market uptake.
Key facts
- 1The UltiSynq lead received FDA approval and a European CE mark. finance.yahoo.com
- 2The ASCEND CSP IDE trial enrolled 205 patients. finance.yahoo.com
- 3Major complication‑free rate at three months was 97.5%. finance.yahoo.com
- 4Lead implantation succeeded in 98.5% of attempts. finance.yahoo.com
- 586% of implanted leads achieved left bundle branch pacing or likely LBBP. finance.yahoo.com
- 6The FDA granted breakthrough device designation to UltiSynq. zacks.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.